Mesoblast Limited (MESO) develops cell-based medicines.
MESO has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions.
MESO’s products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes.
MESO has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.
May 16, 2020 - 12:13pm |
Out and About, Research Notes, Out and About, Earnings Q1
Athersys (ATHX), Homology Medicine (FIXX), Verastem (VSTM), EDITAS Medicine (EDIT), REGENXBIO (RGNX), Caladius Biosciences (CLBS), Bellicum Pharmaceuticals (BLCM),, uniQure (QURE), CRISPR Therapeutics (CRSP),Aduro Biotech (ADRO), Brainstorm Cell Therapeutics (BCLI), Editas medicine (EDIT), Global Blood Therapeutics (GBT), Inyellia Therapeutics (NTLA), Ionis Pharmaceuticals (IONS), Ultragenyx (RARE), Voyager Therapeutics (VYGR), Solid Biosciences (SLDB), MiMedx (MDXG), Stemline Therapeutics (STML) acquired by Menarini, an Italian pharma, Fate therapeutics (FATE), Sangamo Therapeutics (SGMO), bluebird bio (BLUE), BioLife Solutions BLFS, Biostage (BSTG), Pluristem (PSTI)
- May 13, 2020 - 8:59am | Research Notes, Financings
- April 11, 2020 - 1:23pm | Out and About, Research Notes, Out and About, Earnings, Earnings Q4
- September 11, 2018 - 1:18pm | Out and About, Research Notes, Out and About, Earnings, Earnings Q2
- July 2, 2018 - 10:26am | Out and About, Research Notes, Out and About
- June 2, 2018 - 7:11am | Out and About, Out and About, Earnings, Earnings Q1
- March 10, 2018 - 9:22am | Earnings, Earnings Q4
- March 4, 2018 - 11:11am | Analysis, Out and About
- April 4, 2017 - 11:33am | Research Notes
- March 27, 2017 - 12:52pm | Out and About, Research Notes
- March 27, 2017 - 9:25am | Research Notes, Financings
- October 6, 2016 - 7:19am | Research Notes
- August 17, 2016 - 9:55am | Research Notes
- August 9, 2016 - 2:35am | Research Notes
- June 14, 2016 - 5:31pm | Research Notes
- June 14, 2016 - 6:54am | Research Notes
- June 10, 2016 - 8:11am | Research Notes
- June 7, 2016 - 9:57am | Research Notes
- April 1, 2016 - 9:44am | Research Notes, Henry'omics
- March 24, 2016 - 9:49am | Henry'omics, IP & Patents